Skip to content
Search

Latest Stories

DHSC implements process to roll over eligible price concessions from May

Department of Health and Social Care (DHSC) has implemented a process to roll over certain concessionary prices to the following month.

From May 2023, the roll over process will apply to any products where agreement is reached on the final prices granted by DHSC for any price concession requests submitted late in the month (on or after the 23rd of the month) by Community Pharmacy England.


Community Pharmacy England said: "As part of the Year 4 & 5 funding settlement for community pharmacy, it was agreed that an urgent review of the price concession setting system would take place."

It has been working with DHSC to determine improvements to the price concession system.

The following price concessions granted in May 2023 have rolled over to June 2023:

DrugPack SizePrice concession
Chloramphenicol 0.5% eye drops10£9.68
Chlorphenamine 2mg/5ml oral solution sugar free150£3.04
Clotrimazole 500mg pessary and Clotrimazole 2% cream1£10.35
Lansoprazole 30mg orodispersible tablets28£5.52
Methylphenidate 10mg tablets30£3.08
Venlafaxine 150mg modified-release capsules28£4.98
Venlafaxine 150mg modified-release tablets30£4.85
Venlafaxine 75mg modified-release tablets30£2.95

Community Pharmacy England said: “Pharmacy owners (members) will be able to see the lines that have rolled over on our price concessions page here. Please note any rolled over prices can be adjusted upwards if we receive reports from our members to indicate suppliers’ selling prices have increased. The review can be requested at any point during the month.”

“One of the earlier changes agreed between Community Pharmacy England and DHSC was that all products granted a concessionary price will be classified as ‘Discount Not Deducted’ for the month(s) in which they are on concession. From 1 April 2023, a new Group Items category has been added to Part II of the Drug Tariff for ‘Drugs for which discount is not deducted’.

A further solution recently announced by DHSC to help improve current the price concession system includes a ‘retrospective increased payment’ which may apply, when appropriate. We are continuing to seek further improvements to the price concession system.”

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less